Genistein, a Potential Phytochemical against Breast Cancer Treatment-Insight into the Molecular Mechanisms

被引:46
作者
Sohel, Md [1 ,2 ]
Biswas, Partha [3 ,4 ]
Al Amin, Md. [5 ]
Hossain, Md. Arju [5 ]
Sultana, Habiba [5 ]
Dey, Dipta [6 ]
Aktar, Suraiya [7 ]
Setu, Arifa [1 ]
Khan, Md. Sharif [4 ]
Paul, Priyanka [6 ]
Islam, Md. Nurul [8 ]
Rahman, Md. Ataur [9 ,10 ,11 ]
Kim, Bonglee [10 ,11 ]
Al Mamun, Abdullah [1 ]
机构
[1] Mawlana Bhashani Sci & Technol Univ, Dept Biochem & Mol Biol, Tangail 1902, Bangladesh
[2] Pratyasha Hlth Biomed Res Ctr, Dhaka 1230, Bangladesh
[3] Jashore Univ Sci & Technol JUST, Fac Biol Sci & Technol, Dept Genet Engn & Biotechnol, Jashore 7408, Bangladesh
[4] ABEx Biores Ctr, Dhaka 1230, Bangladesh
[5] Mawlana Bhashani Sci & Technol Univ, Dept Biotechnol & Genet Engn, Fac Life Sci, Tangail 1902, Bangladesh
[6] Bangabandhu Sheikh Mujibur Rahman Sci & Technol U, Life Sci Fac, Biochem & Mol Biol Dept, Gopalgonj 8100, Bangladesh
[7] Rajshahi Univ, Dept Biochem & Mol Biol, Rajshahi 6205, Bangladesh
[8] Mawlana Bhashani Sci & Technol Univ, Dept Pharm, Fac Life Sci, Tangail 1902, Bangladesh
[9] Islamic Univ, Fac Biol Sci, Dept Biotechnol & Genet Engn, Global Biotechnol & Biomed Res Network GBBRN, Kushtia 7003, Bangladesh
[10] Kyung Hee Univ, Dept Pathol, Coll Korean Med, Seoul 02447, South Korea
[11] Kyung Hee Univ, Coll Korean Med, Korean Med Based Drug Repositioning Canc Res Ctr, Seoul 02447, South Korea
基金
新加坡国家研究基金会;
关键词
genistein; breast cancer; molecular pharmacology; anticancer mechanism; synergistic activity; SOY ISOFLAVONE GENISTEIN; CELL-CYCLE ARREST; NF-KAPPA-B; PROTEIN-KINASE ACTIVATION; ESTROGEN-RECEPTOR-ALPHA; PHYTOESTROGEN GENISTEIN; IN-VITRO; POSTMENOPAUSAL WOMEN; GROWTH-INHIBITION; PHASE-II;
D O I
10.3390/pr10020415
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Breast cancer (BC) is one of the most common malignancies in women. Although widespread successful synthetic drugs are available, natural compounds can also be considered as significant anticancer agents for treating BC. Some natural compounds have similar effects as synthetic drugs with fewer side effects on normal cells. Therefore, we aimed to unravel and analyze several molecular mechanisms of genistein (GNT) against BC. GNT is a type of dietary phytoestrogen included in the flavonoid group with a similar structure to estrogen that might provide a strong alternative and complementary medicine to existing chemotherapeutic drugs. Previous research reported that GNT could target the estrogen receptor (ER) human epidermal growth factor receptor-2 (HER2) and several signaling molecules against multiple BC cell lines and sensitize cancer cell lines to this compound when used at an optimal inhibitory concentration. More specifically, GNT mediates the anticancer mechanism through apoptosis induction, arresting the cell cycle, inhibiting angiogenesis and metastasis, mammosphere formation, and targeting and suppressing tumor growth factors. Furthermore, it acts via upregulating tumor suppressor genes and downregulating oncogenes in vitro and animal model studies. In addition, this phytochemical synergistically reverses the resistance mechanism of standard chemotherapeutic drugs, increasing their efficacy against BC. Overall, in this review, we discuss several molecular interactions of GNT with numerous cellular targets in the BC model and show its anticancer activities alone and synergistically. We conclude that GNT can have favorable therapeutic advantages when standard drugs are not available in the pharma markets.
引用
收藏
页数:22
相关论文
共 170 条
[21]   Genistein inhibits the proliferation and differentiation of MCF-7 and 3T3-L1 cells via the regulation of ERα expression and induction of apoptosis [J].
Choi, Eun Jeong ;
Jung, Jae Yeon ;
Kim, Gun-Hee .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (02) :454-458
[22]   Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification [J].
Choudhury, Subhasree Roy ;
Karmakar, Surajit ;
Banik, Naren L. ;
Ray, Swapan K. .
INVESTIGATIONAL NEW DRUGS, 2010, 28 (06) :812-824
[23]   Pharmacokinetics of [14C]Genistein in the rat:: Gender-related differences, potential mechanisms of biological action, and implications for human health [J].
Coldham, NG ;
Sauer, MJ .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2000, 164 (02) :206-215
[24]   Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells [J].
Conklin, Chris M. J. ;
Bechberger, John F. ;
MacFabe, Derrick ;
Guthrie, Najla ;
Kurowska, Elzbieta M. ;
Naus, Christian C. .
CARCINOGENESIS, 2007, 28 (01) :93-100
[25]   Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy [J].
Crawford, Sarah .
FRONTIERS IN PHARMACOLOGY, 2013, 4
[26]   Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study [J].
D'Anna, Rosario ;
Cannata, Maria Letizia ;
Atteritano, Marco ;
Cancellieri, Francesco ;
Corrado, Francesco ;
Baviera, Giovanni ;
Triolo, Onofrio ;
Antico, Francesco ;
Gaudio, Agostino ;
Frisina, Nicola ;
Bitto, Alessandra ;
Polito, Francesca ;
Minutoli, Letteria ;
Altavilla, Domenica ;
Marini, Herbert ;
Squadrito, Francesco .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (04) :648-655
[27]   Differences between human breast cell lines in susceptibility towards growth inhibition by genistein [J].
Dampier, K ;
Hudson, EA ;
Howells, LM ;
Manson, MM ;
Walker, RA ;
Gescher, A .
BRITISH JOURNAL OF CANCER, 2001, 85 (04) :618-624
[28]  
Danciu C, 2013, NAT PROD COMMUN, V8, P343
[29]   Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein [J].
de la Parra, Columba ;
Castillo-Pichardo, Linette ;
Cruz-Collazo, Ailed ;
Cubano, Luis ;
Redis, Roxana ;
Calin, George A. ;
Dharmawardhane, Suranganie .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2016, 68 (01) :154-164
[30]  
de Lemos ML, 2001, ANN PHARMACOTHER, V35, P1118, DOI 10.1345/aph.10257